Sino Biopharmaceutical (OTCMKTS:SBMFF) Short Interest Update

Key Points

• Short interest jumped 35.7% in March to 98,069,575 shares, with about 0.5% of the stock sold short and an extraordinary days-to-cover ratio of 212,271.8 days caused by an average daily volume of just 462 shares.
• The stock opened at $0.76 and is trading below its 50- and 200-day moving averages ($0.84 and $0.90), with a 52-week range of $0.45 to $1.24, indicating low price levels and limited liquidity.
• Sino Biopharmaceutical is a Hong Kong–incorporated pharmaceutical holding company focused on R&D, manufacturing and commercialization across three core segments: infusion solutions, small-molecule synthetic drugs and innovative biologics.

Sino Biopharmaceutical (OTCMKTS:SBMFF - Get Free Report) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 98,069,575 shares, an increase of 35.7% from the February 26th total of 72,283,620 shares. Approximately 0.5% of the company's stock are sold short. Based on an average trading volume of 462 shares, the days-to-cover ratio is currently 212,271.8 days.

Sino Biopharmaceutical Stock Performance

SBMFF opened at $0.76 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.28 and a current ratio of 1.36. The firm's 50-day moving average price is $0.84 and its 200-day moving average price is $0.90. Sino Biopharmaceutical has a 52-week low of $0.45 and a 52-week high of $1.24.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited OTCMKTS: SBMFF is a Hong Kong–incorporated investment holding company principally engaged in the pharmaceutical sector. Founded in 2000 and listed on the Hong Kong Stock Exchange in 2006, the company has developed an integrated business model that spans research and development, manufacturing and commercialization of healthcare products. Through its subsidiaries, Sino Biopharmaceutical focuses on enhancing China's domestic pharmaceutical infrastructure while expanding its footprint across key therapeutic areas.

The company's product portfolio is organized into three core segments: infusion solutions, small-molecule synthetic pharmaceuticals and innovative biologics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.